-$0.08 Earnings Per Share Expected for Aethlon Medical, Inc. (AEMD) This Quarter

Wall Street analysts expect that Aethlon Medical, Inc. (NASDAQ:AEMD) will post ($0.08) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aethlon Medical’s earnings, with the lowest EPS estimate coming in at ($0.08) and the highest estimate coming in at ($0.07). Aethlon Medical posted earnings of ($0.06) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 33.3%. The firm is scheduled to report its next earnings results on Friday, June 14th.

According to Zacks, analysts expect that Aethlon Medical will report full-year earnings of ($0.34) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.33). For the next fiscal year, analysts forecast that the business will report earnings of ($0.27) per share, with EPS estimates ranging from ($0.30) to ($0.23). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Aethlon Medical.

An institutional investor recently bought a new position in Aethlon Medical stock. Bank of New York Mellon Corp purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 30,363 shares of the medical equipment provider’s stock, valued at approximately $50,000. Bank of New York Mellon Corp owned 0.17% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 5.33% of the company’s stock.

Shares of AEMD opened at $0.37 on Tuesday. Aethlon Medical has a fifty-two week low of $0.30 and a fifty-two week high of $1.74.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals.

Featured Story: Depreciation

Get a free copy of the Zacks research report on Aethlon Medical (AEMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.